Compare Illumina, Inc. (ILMN) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Transocean Ltd — how do they compare? Illumina, Inc. trades at $189.42 (market cap $27.94B), while Transocean Ltd trades at $5.18 (market cap $5.56B). The key difference: Illumina, Inc. is far larger — about 5× Transocean Ltd's market cap, and Illumina, Inc. is trading nearer its 52-week high, Transocean Ltd nearer its low. Which is the better fit depends on your goals.
| ILMN | RIG | |
|---|---|---|
Market Cap | $27.94B | $5.56B |
Sector | Health | Technology |
52-Week High | $194.33 | $7.58 |
52-Week Low | $91.00 | $2.64 |
Enterprise Value | $29.33B | $10.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Transocean Ltd. (RIG) trades at $5.02, down 2.33% on the day, reflecting a bearish technical trend. The company reported a net loss of $2.92 billion in 2025 despite $3.97 billion in revenue, with a negative net income margin of -66.79%. Recent news highlights a significant $1 billion contract with Equinor and a pending merger with Valaris, aimed at reducing leverage and generating synergies. Analyst consensus is mixed, with a $7.00 price target suggesting potential upside from current levels.
The outlook for RIG hinges on successful execution of its merger and contract backlog conversion to profitability. Opportunities include a strong $7 billion backlog and operational momentum, but risks persist from sustained net losses, high debt, and oil price volatility. Investors should weigh the potential for deleveraging and synergy benefits against ongoing profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
